Biomay Produktions- Und Handelsgesellschaft M.b.h.

Other

Biomay Biotechnik Produktions Und Handelsgesellschaft M.b.h.

Otto Scheiner

Rudolf Valenta

Dietrich Kraft

Michael Breitenbach

Heimo Breiteneder

Helmut Rumpold

Karin Pettenburger

Erika Jensen-Jarolim

Christoph Zielinski

Michael Duchene

Hubert Pehamberger

Hubert Penamberger

The present invention relates to peptides of the extracellular domain of a HER-2/neu protein, conjugates comprising said peptides linked to an immunogenic carrier, compositions thereof, nucleic acid molecules, vectors and transformed or transfected host cells comprising said nucleic acid molecules encoding said peptides or conjugates, and methods for producing the disclosed peptides, conjugates and compositions. The present invention also relates to diagnostic methods of detecting cancerous conditions associated with HER-2/neu or monitoring the effectiveness of treatment against cancerous conditions associated with HER-2/neu. The present invention also relates to methods of eliciting or enhancing an immune response to HER-2/neu in a subject in need thereof.

Vaccine against cancer diseases that are associated with the her-2/neu oncogene

The present invention provides a method for producing a vaccine against cancerous disease, and the vaccine itself. This method involves first using one or more antibodies that are specifically effective against one or more antigens specially expressed by the tumor cells to select one or more mimotopes of said antigens from a phage peptide library. To obtain the vaccine, said mimotopes are conjugated to a macromolecular carrier singly or multiply in the form of their mono-, di-, tri- or oligomers. When administered, the inventively produced vaccine leads to a humoral immune response and thus to the formation of an active immunity as a consequence of vaccination.

Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells

The invention relates to a method by which expression cDNA clone banks are screened by means of IgE antibodies derived from the sera of allergic individuals, or by means of monoclonal or polyclonal antibodies. This type of screening is used for the detection of polynucleotides whose open-reading frames code for allergenically active proteins. These proteins are characterized in that their biological activity as allergens is equal to that of plant allergens occurring in nature.

Method for screening an expression cDNA clone bank for the detection of

The invention relates to a method by which expression cDNA clone banks are screened by means of IgE antibodies derived from the sera of allergic individuals, or by means of monoclonal or polyconal antibodies. This type of screening is used for the detection of polynucleotides whose open-reading frames code for allergenically active proteins. These proteins are characterized in that their biological activity as allergens is equal to that of plant allergens occurring in nature.

Allergens of alder pollen and applications thereof

The invention provides recombinant DNA molecules which code for polypeptides that exhibit the antigenicity of a P14 allergen of birch Betula verrucosa and other plants of the order Fagales, and for polypeptides comprising at least one epitope thereof, as well as nucleic acids which under stringent conditions hybridize with such DNA sequences or are derivable from such sequences by degeneracy of the genetic code. A method is provided that permits purification of P14 allergens or cross reactive allergens by means of binding to poly(L-proline). In addition, methods are described for making the proteins and polypeptides coded by these DNA molecules and their use in the diagnosis or therapy of diseases.

Method of production of birch pollen allergen P14

Birch pollen allergen P14 for diagnosis and therapy of allergic diseases

Growing community of inventors

Mariaenzersdorf, Austria

Otto Scheiner